Global trials are showing strong promise for PARP inhibitors as a new targeted treatment for advanced prostate cancer. Prostate cancer is the second most common cancer in men, with about 1.5 million new cases yearly and numbers expected to rise to 2.4 million by 2040. While early-stage prostate cancer has nearly a 100% 5-year survival rate, this drops to 37% for patients with metastatic disease.
PARP inhibitors target cancer cells with defects in DNA repair, especially those with BRCA1/2 or other homologous recombination repair (HRR) mutations. Around 25% of men with metastatic castration-resistant prostate cancer (mCRPC) have such defects, making them good candidates for this therapy.
In key clinical trials, Olaparib extended median overall survival to 18.5 months compared with 15.1 months in the control group. Rucaparib achieved a 45.7% response rate and a median progression-free survival of 10.7 months. Talazoparib combined with enzalutamide showed a 67% response rate versus 40% in the control group. Common side effects include anemia, nausea, and fatigue.
The success of PARP inhibitors like Olaparib and Rucaparib is changing the outlook for men with advanced prostate cancer. Ongoing research aims to improve combination treatments, overcome resistance, and identify better biomarkers for personalized therapy.